biologic

Lyumjev

insulin lispro-aabc

Loss of exclusivityJune 2032projected — 12-year biologic exclusivity estimate
CompanyEli Lilly and Company

Drug detail

Brand nameLyumjev
Active ingredientinsulin lispro-aabc
Strength300UNITS/3ML (100UNITS/ML)
Dosage formInjection
RouteIntravenous, Subcutaneous
ModalityBiologic
FDA approvalJune 2020
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Lyumjev patent cliff — loss of exclusivity June 2032 | CliffBio